Medical/Pharmaceuticals
Qiming's Portfolio Company CANbridge Pharmaceuticals Lists on Main Board of HKEx
SHANGHAI, Dec. 10, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company CANbridge Pharmaceuticals (SEHK: 1228), a leadingChina-based global rare disease-focused biopharmaceutical company, today listed on the main board of Hong Kong Stock Exchange. The issue price isHK$ 12.18 per share,...
2021-12-10 15:15
5546
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
CASTRES, France, Dec. 10, 2021 /PRNewswire/ -- Today, the final findings of the CONTROL study1 were presented at the 2021 San Antonio Breast Cancer Symposium (SABCS). Results suggest that providing a prophylactic anti-diarrhoea medical treatment or applying a dose escalation schedule of neratinib...
2021-12-10 15:11
3308
Research shows Lianhua Qingwen capsules conferred preventive effects on those exposed to COVID-19
SHIJIAZHUANG, China, Dec. 10, 2021 /PRNewswire/ -- "Lianhua Qingwen capsules conferred preventive effects on those exposed to COVID-19", claimed an article titled "Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Tr...
2021-12-10 12:49
4360
Bora Pharmaceuticals collaborates with Taishin Holdings to launch CDMO investment and M&A plan
TAIPEI, Taiwan, Dec. 8, 2021 /PRNewswire/ -- Bobby Sheng, chairman of Bora Pharmaceuticals (6472.TWO), today announced a partnership with Taishin Healthcare Limited Partnership at the 2021 Biotech Investor Forum, whereby the two parties will jointly invest up toNT$3 billion (approx. US$108 millio...
2021-12-10 12:17
4285
Össur hf: CEO Retirement and Succession Plan
STOCKHOLM, Dec. 10, 2021 /PRNewswire/ -- Jon Sigurdsson to retire after 26 years as Össur President and CEO,Sveinn Sölvason appointed President and CEO successor Jon Sigurdsson has decided to retire from his position as President and CEO of Össur. The Board of Directors has appointed Össur CFO,S...
2021-12-10 07:03
2900
Cordis Names George Adams, MD as Chief Medical Officer
MIAMI LAKES, Fla., Dec. 9, 2021 /PRNewswire/ -- Cordis, a global cardiovascular technology company, today announcedGeorge Adams, MD, MHS, MBA, FACC, FSCAI as Chief Medical Officer, furthering the organization's mission to differentiate itself as a technological leader and value-based global medic...
2021-12-09 23:00
4709
AnchorDx Achieves Academic Breakthrough with Deep Methylation Representation Learning Research Paper Accepted by 36th AAAI Conference
GUANGZHOU, China, Dec. 9, 2021 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer screening and early detection solutions, was accepted on December 1, 2021, to present its "Noninvasive Lung Cancer Early Detection via Deep Methylation Representation Learning" research paper (DeepMeth) at...
2021-12-09 22:00
3457
Trajan to acquire LEAP PAL Parts
MELBOURNE, Australia, Dec. 9, 2021 /PRNewswire/ -- Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) has entered into a binding agreement to acquire the business of LEAP PAL Parts and Consumables, LLC ("LPP"), based in Raleigh North Caro...
2021-12-09 21:00
3110
The innovative software "CAAS vFFR" by Pie Medical Imaging for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III, a multicenter European clinical trial which will investigate the effectiveness of the vessel Fractional Flow Reserve (vFFR) guided revascularization as compared to conventional FFR guided revascularization
MAASTRICHT, Netherlands, Dec. 9, 2021 /PRNewswire/ -- Pie Medical Imaging ("PMI"), a global leader in cardiac imaging, part of the Esaote Group, today announced the beginning of FASTIII, a multicenter randomized clinical trial which willinvestigate the use of angiography-based vessel fractional ...
2021-12-09 21:00
3756
I-Mab to Hold Investor Call to Present In-depth Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma
SHANGHAI and GAITHERSBURG, Md., Dec. 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors at8:00 a.m. EST o...
2021-12-09 21:00
2422
Seegene Rapidly Introduces New PCR Test that Identifies the Omicron Variant, its Stealth Version, and all VOCs in a single tube
SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today unveiled another series of diagnostic test that detects the ever-changing COVID-19 variant landscape. The Novaplex™ SARS-CoV-2 Variants VII assay addresses Omicron...
2021-12-09 20:18
2918
Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients
HANGZHOU, China and SAN FRANCISCO, Dec. 9, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the completion of patient enrollment in its Phase 2 clin...
2021-12-09 20:00
3424
Another clean interim safety review of RhoVac's clinical phase IIb study in prostate cancer
HELSINKI, Dec. 9, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today onDecember 9th, 2021, that its Data & Safety Monitoring Committee (DSMC) has conducted a planned interim safety review of its clinical phase IIb trial in prostate cancer, known as ...
2021-12-09 16:58
1678
Proximie Partners with Jhpiego in New Initiative to Improve Obstetric Surgical Care
- The Obstetric Safe Surgery (OSS) Project in Kenya is funded by Johnson & Johnson and to date has been implemented by Jhpiego as the lead organization, in collaboration with County and National Ministries of Health and professional associations. - To support implementation moving forward, Proxi...
2021-12-09 15:00
5524
Posters Highlighting clinical data of KN026 presented at SABCS 2021
SUZHOU, China, Dec. 9, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced that two posters highlighting data from two clinicalstudies of the anti-HER2 bispecific antibody KN026 were presented at the 44th San...
2021-12-09 12:20
3007
Lunit Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- CB Insights
2021-12-09 11:24
3033
Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021
- Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine therapy in overall population and estrogen receptor mutation (mESR1) population - In the overall p...
2021-12-09 08:38
3695
WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan
SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced that it is a recipient of the 2021 Global CRDMO Customer Value Leadership Award from Frost & Sullivan, a global ...
2021-12-09 08:00
3271
Servatus raises $7.5 million to advance autoimmune therapies with its microbial biotherapeutics clinical programs
* Servatus has raised $7.5 million in an oversubscribed capital raise, with strong support from sophisticated shareholders * Funds raised will underpin Servatus' live microbial and engineered protein biotherapeutics drug development * Two Phase 1/2 clinical trials to launch shortly in Queens...
2021-12-09 07:35
3736
Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China
The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment inChina, through a randomized, double-blind and placebo-controlled trial Brii Bio is also seeking U.S. FDA Emergency Use Authorization for the amubarvimab/romlusevimab combination DURHAM, N.C. and ...
2021-12-09 06:10
4497
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 281 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 267 media titles]
2026-09-30 10:50
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 267 media titles]
2026-10-01 10:00
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
23044
